Compare PCT & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PCT | HRMY |
|---|---|---|
| Founded | 2015 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Environmental Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.0B |
| IPO Year | N/A | 2020 |
| Metric | PCT | HRMY |
|---|---|---|
| Price | $8.92 | $37.65 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | $13.67 | ★ $51.33 |
| AVG Volume (30 Days) | ★ 4.0M | 779.7K |
| Earning Date | 11-06-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.44 |
| EPS | N/A | ★ 3.17 |
| Revenue | $5,660,000.00 | ★ $825,944,000.00 |
| Revenue This Year | N/A | $23.11 |
| Revenue Next Year | $689.83 | $16.15 |
| P/E Ratio | ★ N/A | $11.94 |
| Revenue Growth | N/A | ★ 21.13 |
| 52 Week Low | $5.40 | $25.52 |
| 52 Week High | $17.37 | $40.93 |
| Indicator | PCT | HRMY |
|---|---|---|
| Relative Strength Index (RSI) | 48.04 | 56.93 |
| Support Level | $7.43 | $37.12 |
| Resistance Level | $9.71 | $40.87 |
| Average True Range (ATR) | 0.63 | 1.36 |
| MACD | 0.09 | -0.32 |
| Stochastic Oscillator | 64.58 | 40.59 |
PureCycle Technologies Inc is a Florida-based corporation focused on commercializing a patented dissolution process to physically separate the polymer from other plastics, color, and contaminants (the Technology), originally developed by The Procter & Gamble Company (P&G), for restoring waste polypropylene into resin with near-virgin characteristics, called PureFive resin. PureFive resin represents the family of recycled resin products produced, including ultra-pure resin and other grades used for compounding to meet customer specifications, which has similar properties and applicability for reuse as virgin polypropylene. It has a single operating segment, which encompasses integrated business activities related to the recycling of polypropylene into resins.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.